Health Condition 1: B079- Viral wart, unspecified
Conditions
Interventions
Intervention1: MMR vaccine: Intralesional Measles, Mumps, and Rubella (MMR) Vaccine (0.5 mL of reconstituted MMR vaccine) in extragenital cutaneous warts.
Intervention2: BCG vaccine: Intralesional Bac
600,000 IU
15 mg/mL) in extragenital cutaneous warts.
Control Intervention1: efficacy between Group A, Group B, group C were compared: Intralesional Measles, Mumps, and Rubella (MMR) Vaccine (0.5 mL of reconstit
15 mg/mL) in extragenital cutaneous warts.
Sponsors
Dr Nimisha Kabra self
Eligibility
Inclusion criteria
Inclusion criteria: patients aged between 12 and 65 years, who presented to the dermatology outpatient department at Indira Gandhi Institute of Medical Sciences, Patna, with clinically diagnosed extragenital cutaneous warts. Eligibility criteria required participants to have more than two warts and no history of wart treatment within the past four weeks
Exclusion criteria
Exclusion criteria: The study excluded pregnant or breastfeeding women, individuals with immunosuppression due to underlying diseases or medications, patients with mucosal warts, those who did not consent, individuals with severe organ dysfunction, those unable to attend monthly follow-ups, and users of alcohol or other substances
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcomes will be assessed in the context of resolution of warts in size and number with the help of photographic images and visual analog scale score. Timepoint: Patient assessment at every 3 weeks for maximum 5 sessions. then every month for 2 months to check for recurrence | — |
Secondary
| Measure | Time frame |
|---|---|
| To note for recurrences in follow up of 2 months with adverse effects.Timepoint: Adverse effects noted at each follow up( 3 weekly), and recurrence in 2 months after complete response. | — |
Countries
India
Contacts
Public ContactNimisha Kabra
Indira Gandhi Institute of medical sciences, Patna
Outcome results
None listed